209 related articles for article (PubMed ID: 10956406)
1. Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse.
Sugano K; Ushiama M; Fukutomi T; Tsuda H; Kitoh T; Ohkura H
Int J Cancer; 2000 Jul; 89(4):329-36. PubMed ID: 10956406
[TBL] [Abstract][Full Text] [Related]
2. Serum c-erbB-2 protein is a useful marker for monitoring tumor recurrence of the breast.
Imoto S; Wada N; Hasebe T; Ochiai A; Kitoh T
Int J Cancer; 2007 Jan; 120(2):357-61. PubMed ID: 17044019
[TBL] [Abstract][Full Text] [Related]
3. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value.
Molina R; Jo J; Filella X; Zanon G; Pahisa J; Mu noz M; Farrus B; Latre ML; Escriche C; Estape J; Ballesta AM
Breast Cancer Res Treat; 1998 Sep; 51(2):109-19. PubMed ID: 9879773
[TBL] [Abstract][Full Text] [Related]
4. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
6. Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3.
Molina R; Jo J; Zanón G; Filella X; Farrus B; Muñoz M; Latre ML; Pahisa J; Velasco M; Fernandez P; Estapé J; Ballesta AM
Br J Cancer; 1996 Oct; 74(7):1126-31. PubMed ID: 8855986
[TBL] [Abstract][Full Text] [Related]
7. Serum and immunohistochemical studies of NCC-ST-439 in breast cancer.
Narita T; Funahashi H; Satoh Y; Imai T; Takagi H
J Surg Oncol; 1993 Sep; 54(1):5-8. PubMed ID: 8377506
[TBL] [Abstract][Full Text] [Related]
8. C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients.
Molina R; Jo J; Filella X; Zanón G; Farrus B; Muñoz M; Latre ML; Pahisa J; Velasco M; Fernandez P; Estapé J; Ballesta AM
Anticancer Res; 1999; 19(4A):2551-5. PubMed ID: 10470193
[TBL] [Abstract][Full Text] [Related]
9. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
[TBL] [Abstract][Full Text] [Related]
10. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
[TBL] [Abstract][Full Text] [Related]
11. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
12. Serum c-erbB-2 in breast cancer patients.
Watanabe N; Miyamoto M; Tokuda Y; Kubota M; Ando Y; Tajima T; Mitomi T
Acta Oncol; 1994; 33(8):901-4. PubMed ID: 7818922
[TBL] [Abstract][Full Text] [Related]
13. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
Shao Y; Sun X; He Y; Liu C; Liu H
PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
[TBL] [Abstract][Full Text] [Related]
14. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
15. The potential use of saliva to detect recurrence of disease in women with breast carcinoma.
Bigler LR; Streckfus CF; Copeland L; Burns R; Dai X; Kuhn M; Martin P; Bigler SA
J Oral Pathol Med; 2002 Aug; 31(7):421-31. PubMed ID: 12165061
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer.
Pedersen AC; Sørensen PD; Jacobsen EH; Madsen JS; Brandslund I
Clin Chem Lab Med; 2013 Jul; 51(7):1511-9. PubMed ID: 23403727
[TBL] [Abstract][Full Text] [Related]
17. Serum c-erB-2 levels in monitoring of operable breast cancer patients.
Imoto S; Kitoh T; Hasebe T
Jpn J Clin Oncol; 1999 Jul; 29(7):336-9. PubMed ID: 10470658
[TBL] [Abstract][Full Text] [Related]
18. The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study.
Streckfus C; Bigler L; Dellinger T; Dai X; Kingman A; Thigpen JT
Clin Cancer Res; 2000 Jun; 6(6):2363-70. PubMed ID: 10873088
[TBL] [Abstract][Full Text] [Related]
19. Measurement of c-erbB-2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: correlation with serum tumor markers and membrane-bound oncoprotein.
Wu JT; Astill ME; Gagon SD; Bryson L
J Clin Lab Anal; 1995; 9(3):151-65. PubMed ID: 7541455
[TBL] [Abstract][Full Text] [Related]
20. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen.
Safi F; Kohler I; Röttinger E; Beger H
Cancer; 1991 Aug; 68(3):574-82. PubMed ID: 2065278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
